Security
Universe Pharmaceuticals Inc. Class A Ordinary Shares · UPC
UPCNASDAQCommon stockCurrentCIK 1809616Updated Oct 14, 2026
UPC price & chart
Loading TradingView…
NASDAQ:UPC on TradingView ↗About the company
Universe Pharmaceuticals INC, headquartered in Ji’an, Jiangxi, China, is a pharmaceutical producer and distributor in China. The Company specializes in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the aging process and to promote their general well-being. The Company also distributes and sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Currently, the Company’s products are sold in 30 provinces of China. For more information, visit the company’s website at http://www.universe-pharmacy.com/.
In the news
No coverage from other publishers is available.
Seeking Alpha
Recent filings
EFFECT filing
6-K filing
F-3 filing
6-K/A filing
SCHEDULE 13G - filed by Chen Xuncheng regarding Universe Pharmaceuticals INC
Show 5 more recent filings
SCHEDULE 13G - filed by Li Xuefeng regarding Universe Pharmaceuticals INC
SCHEDULE 13G - filed by Lu Shanshan regarding Universe Pharmaceuticals INC
SCHEDULE 13G - filed by Xie Shan regarding Universe Pharmaceuticals INC
SCHEDULE 13G - filed by Ye Piao regarding Universe Pharmaceuticals INC
SCHEDULE 13G - filed by Yang Lu (nmn) regarding Universe Pharmaceuticals INC
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q2 2024 | Q2 2023 | Q2 2022 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| AssetsUSD | 49,431,114Source | 70,368,331Source | — | 69,303,440,000Source | 67,953,393Source | 53,287,032Source | 59,539,875Source |
| Property, Plant and Equipment, NetUSD | 3,522,997Source | 4,144,360Source | — | 3,583,553,000Source | 3,568,050Source | 3,699,965Source | 4,250,638Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 147,652Source | 160,470Source | — | 296,785,000Source | 262,878Source | 148,584Source | 157,451Source |
| Current assets: | |||||||
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 14,384,228Source | 17,519,268Source | — | 13,008,117,000Source | 12,905,821Source | 10,667,603Source | 15,183,890Source |
| Inventory, NetUSD | 3,386,052Source | 2,868,248Source | — | 2,193,179,000Source | 1,737,054Source | 3,343,266Source | 2,206,488Source |
| Assets, CurrentUSD | 33,530,133Source | 52,515,213Source | — | 53,603,675,000Source | 51,637,784Source | 36,810,218Source | 41,505,680Source |
| Prepaid Expense and Other Assets, CurrentUSD | 539,240Source | 2,010,285Source | — | 39,937,000Source | 852,417Source | 626,241Source | — |
| LIABILITIES AND EQUITY | |||||||
| LiabilitiesUSD | 22,687,018Source | — | — | 13,173,930,000Source | 22,450,452Source | — | — |
| Stockholders’ equity: | |||||||
| Common Stock, Value, IssuedUSD | 68,362Source | 67,969Source | — | 6,337,553,000Source | 482,400Source | 67,969Source | 67,969Source |
| Additional Paid in CapitalUSD | — | 29,279,159Source | — | — | — | — | 29,279,159Source |
| Retained Earnings (Accumulated Deficit)USD | -2,942,153Source | 15,606,938Source | — | -13,843,623,000Source | -10,171,568Source | 10,159,304Source | 16,322,365Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -2,100,414Source | -266,930Source | — | -1,813,522,000Source | -1,112,146Source | -2,413,266Source | -1,666,705Source |
| Stockholders' Equity Attributable to ParentUSD | 26,744,096Source | 47,126,671Source | 61,158,282Source | 56,129,510,000Source | 45,502,941Source | 39,532,701Source | 46,442,323Source |
| Additional Paid in Capital, Common StockUSD | 29,278,766Source | — | — | 63,009,567,000Source | 53,864,720Source | 29,279,159Source | — |
| Liabilities and EquityUSD | 49,431,114Source | 70,368,331Source | — | 69,303,440,000Source | 67,953,393Source | 53,287,032Source | 59,539,875Source |
| Current liabilities: | |||||||
| Liabilities, CurrentUSD | 20,609,542Source | 23,241,660Source | — | 13,173,930,000Source | 20,312,969Source | 13,754,331Source | 13,097,552Source |
| Accounts Payable, CurrentUSD | 7,763,981Source | 11,239,025Source | — | 1,669,785,000Source | 4,914,762Source | 4,585,285Source | 3,075,393Source |
| Additional Financial Items | |||||||
| Accounts Receivable, after Allowance for Credit LossUSD | 11.7Source | — | — | 6,600,000Source | 12,800,000Source | 6.5Source | 15,183,890Source |
| Long-term Debt, Current MaturitiesUSD | — | — | — | 2,107,038,000Source | — | — | — |
| Short-term InvestmentsUSD | 2,527,603Source | 13,314,902Source | — | — | — | 13,219,005Source | 13,148,594Source |
cash flow · annual statements
| Line item | Q2 2024 | Q2 2023 | Q2 2022 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -8,736,566Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | 517,431,000Source | 485,734Source | 508,785Source | 533,949Source |
| Changes in operating assets and liabilities: | |||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | 168,958,000Source | 1,547,834Source | -4,718,118Source | 1,549,312Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | 474,633,000Source | -1,643,131Source | 1,183,823Source | -16,586Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | -3,132,705,000Source | 143,747Source | 1,641,426Source | -1,896,621Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | 606,704Source | 679,586Source | -605,278Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | -5,052,319,000Source | -9,506,683Source | 1,120,082Source | -1,312,346Source |
| Cash flows from investing activities: | |||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | -341,807,000Source | -361,285Source | -44,169Source | -3,908,105Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | 266,771,000Source | 208,320Source | 44,169Source | 93,703Source |
| Cash flows from financing activities: | |||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | 9,726,130,000Source | 33,954,325Source | -1,390,646Source | 3,317,943Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | 4,094,332,000Source | 24,212,446Source | -426,211Source | -2,366,450Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 8,861,590Source | 12,954,516Source | 14,236,300Source | 33,592,025,000Source | 29,497,693Source | 5,285,247Source | 5,711,458Source |
| Supplemental disclosure of cash flow information: | |||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | 289,385,000Source | 304,516Source | 190,184Source | 199,852Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | -237,672,000Source | 126,089Source | -111,478Source | -463,942Source |
| Additional Financial Items | |||||||
| Amortization of Intangible AssetsUSD | — | — | — | 43,253,000Source | 11,700Source | 5,098Source | 5,030Source |
| DepreciationUSD | — | — | — | 474,178,000Source | 474,034Source | 503,687Source | 528,919Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | -114Source | 983Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | -2,948,000Source | -3,958Source | — | — |
| General and Administrative ExpenseUSD | — | — | — | 3,747,705,000Source | 2,889,652Source | 2,199,657Source | 2,602,624Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | 65,058,000Source | 31,942Source | 31,072Source | 38,588Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | 606,704Source | 2,313,487Source | 752,419Source |
| InterestExpenseNonoperatingUSD | — | — | — | 232,041,000Source | 278,172Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | — | -3,672,055,000Source | -8,727,298Source | -6,163,061Source | -8,736,566Source |
| Nonoperating Income (Expense)USD | — | — | — | -756,136,000Source | -100,754Source | — | — |
| Operating ExpensesUSD | — | — | — | 9,217,088,000Source | 14,091,742Source | 13,841,908Source | 29,330,134Source |
| Other Nonoperating Income (Expense)USD | — | — | — | -108,044,000Source | 145,476Source | -322,800Source | -545,349Source |
| Other Operating Income (Expense), NetUSD | — | — | — | — | — | -235,614Source | 48,940Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 15,000,000,000Source | 24,999,992Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 17,858,732,000Source | 23,024,458Source | 32,308,735Source | 40,143,151Source |
| Cost of RevenueUSD | 11,557,563,000Source | 16,952,556Source | 21,993,601Source | 16,154,974Source |
| Operating Income (Loss)USD | -2,915,919,000Source | -8,019,840Source | -3,526,774Source | — |
| Other Nonoperating Income (Expense)USD | -108,044,000Source | 145,476Source | -322,800Source | -545,349Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -3,672,055,000Source | -8,120,594Source | -3,849,574Source | -7,984,147Source |
| Income Tax Expense (Benefit)USD | — | 606,704Source | 2,313,487Source | 752,419Source |
| Net Income (Loss) Attributable to ParentUSD | -3,672,055,000Source | -8,727,298Source | -6,163,061Source | -8,736,566Source |
| Earnings Per Share, BasicUSD per share | -8.06Source | -626.96Source | -1.7Source | -0.4Source |
| Earnings Per Share, DilutedUSD per share | -8.06Source | -626.96Source | -1.7Source | -0.4Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 455,871Source | 13,920Source | 3,625,000Source | 21,750,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 455,871Source | 13,920Source | 3,625,000Source | 21,750,000Source |
| Interest Expense (non-operating)USD | 232,041,000Source | 278,172Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 43,253,000Source | 11,700Source | 5,098Source | 5,030Source |
| Current Income Tax Expense (Benefit)USD | — | — | 685,937Source | 1,357,697Source |
| General and Administrative ExpenseUSD | 3,747,705,000Source | 2,889,652Source | 2,199,657Source | 2,602,624Source |
| Gross ProfitUSD | 6,301,169,000Source | 6,071,902Source | 10,315,134Source | 21,891,336Source |
| Income (Loss) from Equity Method InvestmentsUSD | 65,058,000Source | 31,942Source | 31,072Source | 38,588Source |
| Interest ExpenseUSD | 289,385,000Source | — | 156,788Source | 162,400Source |
| Investment Income, NetUSD | — | — | 38,530Source | — |
| Net Investment IncomeUSD | — | — | 31,072Source | 38,588Source |
| Nonoperating Income (Expense)USD | -756,136,000Source | -100,754Source | — | — |
| Operating ExpensesUSD | 9,217,088,000Source | 14,091,742Source | 13,841,908Source | 29,330,134Source |
| Other Operating Income (Expense), NetUSD | — | — | -235,614Source | 48,940Source |
| Research and Development ExpenseUSD | 671,761,000Source | 3,031,115Source | 4,858,548Source | 7,644,375Source |
| Selling ExpenseUSD | 4,797,622,000Source | 8,170,975Source | 6,783,703Source | 19,083,135Source |
Offerings
Registration 333-299191
Filing attachments
ea030676001ex4-1.htm · F-3 · 2026-09-29
Exhibit 4.1 SHARE CERTIFICATE Number Shares Universe Pharmaceuticals INC 大自然藥業股份有限公司 THIS SHARE CERTIFICATE CERTIFIES THAT as of [Transfer date], [Name] of [Address] is the registered holder of [Number] fully paid Class A ordinary share(s) of $0.00001 par value per share in the above named Company which are held subject to, and transferable in accordance with, the Amended and Restated Memorandum and Articles of Association of the Company (as Revised). In Witness Whereof the Company …
Read attachment ↗ea030676001ex4-5.htm · F-3 · 2026-09-29
Exhibit 4.5 Universe Pharmaceuticals INC (the “Issuer”) AND [TRUSTEE] (the “Trustee”) INDENTURE Dated as of [●], 20[●] Senior Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.…
Read attachment ↗ea030676001ex4-6.htm · F-3 · 2026-09-29
Exhibit 4.6 UNIVERSE PHARMACEUTICALS INC (the “Issuer”) AND [TRUSTEE] (the “Trustee”) INDENTURE Dated as of [●], 20[●] Subordinated Debt Securities TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms …
Read attachment ↗ea030457101ex99-1.htm · 6-K/A · 2026-09-03
Exhibit 99.1 Universe Pharmaceuticals INC (an exempted company with limited liability incorporated in the Cayman Islands) (Nasdaq: UPC) NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN THAT the annual general meeting (the “ Meeting ”) of the holders (the “ shareholders ”) of Class A ordinary shares of par value US$0.00001 each (the “ Class A Ordinary Shares ”) and Class B ordinary shares of par value US$0.00001 each ( the “ Class B Ordinary Shares ” and, together with…
Read attachment ↗ea030397108ex99-1.htm · SCHEDULE 13G · 2026-09-01
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Class A ordinary shares of Universe Pharmaceuticals INC, a Cayman Islands exempted company, and that this Ag…
Read attachment ↗ea030397107ex99-1.htm · SCHEDULE 13G · 2026-09-01
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Class A ordinary shares of Universe Pharmaceuticals INC, a Cayman Islands exempted company, and that this Ag…
Read attachment ↗